RecruitingPhase 4ACTRN12621001764820

Alfentanil versus fentanyl with ketamine for emergency department rapid sequence intubation: The A-FAKT study, a randomised clinical trial.

A comparison of alfentanil with fentanyl on the post-induction haemodynamics of patients undergoing rapid sequence intubation with ketamine and rocuronium in the emergency department: The A-FAKT study, a pilot randomised controlled trial.


Sponsor

South West Sydney Local Health District

Enrollment

60 participants

Start Date

Aug 12, 2022

Study Type

Interventional

Conditions

Summary

A small number of patients presenting to emergency departments need intubation, a process to place a tube in their windpipe to protect their airway, and allow breathing support with a ventilator. Drugs are used to ensure that they are unconscious and to relax their muscles to make placement of the tracheal tube possible, but these drugs can cause changes to vital signs such as pulse and blood pressure, which could worsen their condition. Ketamine is often used as a sedative agent for intubation, and an opioid (morphine-like) drug is sometimes used to try and normalise the blood pressure during the procedure. Fentanyl is the most commonly used opioid for this purpose, but another drug called alfentanil is theoretically a better choice. In this clinical trial, we intend to randomise patients to receive equivalent doses of either fentanyl or alfentanil, in a blinded fashion, as part of a drug regimen with ketamine and a muscle relaxant called rocuronium. The study aims to test the null hypothesis that there is no difference in the outcomes measured between fentanyl and alfentanil.


Eligibility

Sex: Both males and femalesMin Age: 18 Yearss

Inclusion Criteria1

  • Adult patients (18 years or older) undergoing rapid sequence intubation in participating emergency departments where the treating clinician intends to use an opioid in combination with ketamine and rocuronium.

Exclusion Criteria6

  • Allergy to study medications.
  • Hypotensive at baseline (SBP <100 mmHg) or shock index (pulse/SBP >1.0)
  • No doctor trained in the study protocol available to oversee.
  • Alternative induction regime required in the judgment of the treating doctor.
  • Overwhelmed emergency department in the judgment of the treating doctor.
  • COVID or suspected COVID infection.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

Arm one will receive 2.5 - 15 micrograms per kilogram of alfentanil intravenously in addition to ketamine and rocuronium to facilitate rapid sequence intubation. The bolus of alfentanil will be given

Arm one will receive 2.5 - 15 micrograms per kilogram of alfentanil intravenously in addition to ketamine and rocuronium to facilitate rapid sequence intubation. The bolus of alfentanil will be given immediately prior to the other medications in the regimen (ketamine, followed by rocuronium) without a significant pause between. The volume of intravenous alfentanil administered will be the equivalent that the treating doctor would administer if using open label fentanyl in a concentration of 10 micrograms per millilitre. I.e. if the treating doctor would aim to administer 100 micrograms of open label fentanyl (10 ml in the concentration used in this study), they would administer 10 ml (containing 500 mcg) of alfentanil in this arm. The volume of medication administered will be recorded on the case report form, and also in a separate controlled drugs register, which will be checked by two independent staff members.


Locations(3)

Liverpool Hospital - Liverpool

NSW, Australia

Campbelltown Hospital - Campbelltown

NSW, Australia

The Northern Beaches Hospital - Frenchs Forest

NSW, Australia

View Full Details on ANZCTR

For the most up-to-date information, visit the official listing.

Visit

ACTRN12621001764820


Related Trials